Contact
searchSearch
HMP Global

Multiple Sclerosis Topic Center

A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
A doctor looks at a brain scan
News
Obexelimab for Relapsing MS Meets Primary Endpoint in Phase 2 Trial
11/04/2025
Brionna Mendoza
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial...
11/04/2025
Neurology
an older woman sits on a couch looking out the window
News
Menopause Not Associated With Disease Progression in MS
10/10/2025
Brionna Mendoza
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive...
10/10/2025
Neurology
a head in profile with a heart over where the brain would be against a teal background
News
Multiple Sclerosis May Increase Risk for Alzheimer Disease
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
In Pediatric Onset Multiple Sclerosis, Biological Aging May Be Accelerated
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
Biomarker Combo Predicts MS in Patients With Radiologically Isolated Syndrome
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
Long COVID Symptoms Persist in Individuals With Multiple Sclerosis, Study Finds
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
Injectable Medication
News
MS Drug Associated with Rare Cases of Anaphylaxis, FDA Warns
02/06/2025
Jolynn Tumolo
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare,...
02/06/2025
Neurology

Migraine CME Series

News

A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
A doctor looks at a brain scan
News
Obexelimab for Relapsing MS Meets Primary Endpoint in Phase 2 Trial
11/04/2025
Brionna Mendoza
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial...
11/04/2025
Neurology
an older woman sits on a couch looking out the window
News
Menopause Not Associated With Disease Progression in MS
10/10/2025
Brionna Mendoza
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive...
10/10/2025
Neurology
a head in profile with a heart over where the brain would be against a teal background
News
Multiple Sclerosis May Increase Risk for Alzheimer Disease
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
In Pediatric Onset Multiple Sclerosis, Biological Aging May Be Accelerated
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
Biomarker Combo Predicts MS in Patients With Radiologically Isolated Syndrome
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
Long COVID Symptoms Persist in Individuals With Multiple Sclerosis, Study Finds
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
Injectable Medication
News
MS Drug Associated with Rare Cases of Anaphylaxis, FDA Warns
02/06/2025
Jolynn Tumolo
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare,...
02/06/2025
Neurology
a woman holds another person's hand for support
News
Suicidality at Epilepsy Diagnosis Predicts Future Drug Resistance Risk
03/16/2026
Maria Mantas
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found...
03/16/2026
Neurology
A woman lies on the couch holding an ice pack to her head
News
Migraine Nearly Doubles Depression and Anxiety Risk in Cohort Study
03/10/2026
Brionna Mendoza
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2...
03/10/2026
Psych Congress Network
A nurse and a doctor review information on a computer in a lab clinical study research trial
News
Fenebrutinib for Multiple Sclerosis Returns Significant Phase III Results
03/04/2026
Brionna Mendoza
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1...
03/04/2026
Neurology
a bowl of fruits and vegetables indicates brain health
News
DASH Diet Linked to Lower Subjective Cognitive Decline Risk
03/02/2026
Maria Mantas
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of...
03/02/2026
Neurology
a colorful illustration of the brain
News
Five-Year Ublituximab Efficacy Sustained in Relapsing MS Trial
02/23/2026
Maria Mantas
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained...
02/23/2026
Neurology
a row of pill bottles on a shelf
News
Cenobamate Shows Superior Effectiveness in Drug-Resistant Focal Epilepsy
02/17/2026
Maria Mantas
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found...
02/17/2026
Neurology
Two doctors review research data on a computer in a lab
News
Intravenous Tenecteplase Improves Functional Outcomes in Extended-Window Non-LVO Stroke
02/12/2026
Brionna Mendoza
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical...
02/12/2026
Neurology
a doctor reviews brain scans
News
Phase 2 Odatroltide Trials Show Promise for Acute Ischemic Stroke Patients
02/09/2026
Maria Mantas
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials...
02/09/2026
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
a mother and daughter sit at a table
News
Fremanezumab Reduces Migraine Days in Pediatric Episodic Migraine
01/30/2026
Maria Mantas
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized,...
01/30/2026
Neurology

Alzheimer's Disease CME Series

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use